Anika Therapeutics Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Anika Therapeutics de 70% y 6.7% respectivamente, mientras que el BPA crecerá en un 88.3% al año.

Información clave

88.0%

Tasa de crecimiento de los beneficios

84.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.8%
Tasa de crecimiento de los ingresos	6.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	09 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

May 28

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18

Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ANIK - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	194	9	28	N/A	2
12/31/2025	182	9	16	21	3
12/31/2024	171	-4	7	12	3
3/31/2024	169	-77	-4	2	N/A
12/31/2023	167	-83	-7	-2	N/A
9/30/2023	163	-25	-11	-5	N/A
6/30/2023	162	-22	-16	-9	N/A
3/31/2023	157	-22	-5	3	N/A
12/31/2022	156	-15	-3	4	N/A
9/30/2022	152	-16	2	8	N/A
6/30/2022	152	-11	2	8	N/A
3/31/2022	150	-2	3	9	N/A
12/31/2021	148	4	3	8	N/A
9/30/2021	145	-6	2	7	N/A
6/30/2021	137	-13	7	10	N/A
3/31/2021	129	-27	8	10	N/A
12/31/2020	130	-24	11	13	N/A
9/30/2020	128	-4	22	24	N/A
6/30/2020	126	11	26	28	N/A
3/31/2020	125	28	27	30	N/A
12/31/2019	115	27	34	37	N/A
9/30/2019	112	31	31	34	N/A
6/30/2019	109	29	31	35	N/A
3/31/2019	109	30	31	34	N/A
12/31/2018	106	19	30	35	N/A
9/30/2018	108	19	25	32	N/A
6/30/2018	108	18	25	33	N/A
3/31/2018	111	20	25	35	N/A
12/31/2017	113	32	N/A	41	N/A
9/30/2017	113	32	N/A	40	N/A
6/30/2017	111	34	N/A	39	N/A
3/31/2017	104	31	N/A	32	N/A
12/31/2016	103	33	N/A	24	N/A
9/30/2016	106	36	N/A	34	N/A
6/30/2016	103	35	N/A	31	N/A
3/31/2016	100	34	N/A	43	N/A
12/31/2015	93	31	N/A	40	N/A
9/30/2015	85	28	N/A	39	N/A
6/30/2015	84	25	N/A	37	N/A
3/31/2015	87	27	N/A	30	N/A
12/31/2014	106	38	N/A	40	N/A
9/30/2014	104	37	N/A	33	N/A
6/30/2014	99	36	N/A	33	N/A
3/31/2014	94	33	N/A	33	N/A
12/31/2013	75	21	N/A	25	N/A
9/30/2013	76	18	N/A	22	N/A
6/30/2013	73	15	N/A	17	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ANIK sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que ANIK sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ANIK sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (6.7% al año) de ANIK crezcan más despacio que el mercado de US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.7% al año) de ANIK crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ANIK se prevé que sea elevada dentro de 3 años.

Anika Therapeutics Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 39%

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

Consensus forecasts updated

Recent updates

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Announces CFO Changes

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

President exercised options and sold US$717k worth of stock

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States

Consensus EPS estimates fall by 39%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

President exercised options and sold US$345k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Anika Therapeutics, Inc.’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

Anika Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Anika Announces First Surgeries Performed Using the X-Twist Fixation System and Commences Limited Market Release

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$40.50

Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022

President recently bought US$207k worth of stock

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Anika Therapeutics, Inc. Provides Revenue Guidance for Fiscal 2022

Price target decreased to US$43.75

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider exercised options and sold US$55k worth of stock

Anika Therapeutics, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: EPS US$0.039 (vs US$0.45 loss in 3Q 2020)

Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.54 loss in 2Q 2020)

Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Independent Director Joseph Bower has left the company

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

Independent Director recently sold US$85k worth of stock

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.41 in 1Q 2020)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Full year 2020 earnings released: US$1.69 loss per share (vs US$1.93 profit in FY 2019)

Earnings beat expectations, revenue disappoints

Insider exercised options and sold US$64k worth of stock

New 90-day low: US$35.54

Anika Therapeutics, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

New 90-day high: US$45.26

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

New 90-day high: US$39.27

New 90-day high: US$39.04

Independent Director recently sold US$127k worth of stock

Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation